Abbott Laboratories (ABT)

Over the past six months, Abbott Laboratories' stock experienced fluctuations, with a share price of $125.92 as of January 9, 2026, representing an 11.25% increase over the past year but recent decreases of 1.02% in the past month and 6.13% over the past three months. The third-quarter 2025 earnings report, released on October 15, 2025, showed a 6.9% increase in sales but a narrowed full-year adjusted earnings outlook, leading to a drawdown of approximately -2.9% in trading. Analysts maintain confidence with an average target price of $144.26 as of January 9, 2026.

While specific product demand seasonality is not explicitly detailed, Abbott Laboratories experiences fluctuating demand in certain areas, such as a decline in sales due to lower demand for COVID-19-related testing in 2023. The nutrition segment, especially adult nutrition products, has seen strong growth internationally, and the medical devices segment, particularly Diabetes Care with the FreeStyle Libre, has been a significant growth driver. The company uses demand planning specialists to manage these variations.

Abbott Laboratories is a multinational medical devices and healthcare company based in Abbott Park, Illinois, operating in medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. Its product range includes pediatric and adult nutritionals, core lab and rapid diagnostics, and medical devices for rhythm management, heart failure, neuromodulation, and diabetes care, along with branded generic medicines.

Abbott Laboratories has a significant global presence, operating in over 160 countries, with 38.53% of its revenue coming from the United States in fiscal year 2024. Approximately 70% of Abbott's revenue is generated from outside the U.S., highlighting its extensive international exposure to both mature and emerging markets.

Abbott Laboratories maintains a strong brand reputation through innovation and contributions to medical science, including the rapid development of COVID-19 diagnostic tests. The company's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by 2030. The FreeStyle Libre system received the Prix Galien Golden Jubilee Award, and recent product launches like the TriClip and Navitor TAVI system underscore its ongoing innovation in cardiovascular health.

Abbott Laboratories is primarily held by institutional owners, who possess approximately 77.82% of the shares, with Vanguard Group Inc being the largest individual institutional shareholder at 9.96%. Insiders own about 1.14%, while retail investors hold approximately 21.04% of the stock.